Back to top

BioMarin Pharmaceutical (BMRN)

Read MoreHide Full Article

We are downgrading BioMarin Pharmaceutical Inc. (BRMN) to Underperform from Neutral purely on valuation grounds as we believe that the stock is overvalued at current levels. Moreover, we are disappointed by the initial sales ramp of the company's newest marketed product - Firdapse.

Moreover, we expect cash burn to increase since the company is investing heavily in its pipeline. Any negative news regarding the pipeline would have an adverse impact on the stock.

These concerns have caused us to widen our loss estimate for 2012 by $0.32 to $0.39 per share. Since we believe the stock is overvalued at current levels, we advise investors to avoid the name. Our target price is $35.00.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BioMarin Pharmaceutical Inc. (BMRN) - free report >>


More from Zacks Bear of the Day

You May Like